Anaheim, CA – January 31, 2017—Clinical study results presented at the Society of Critical Care Medicine (SCCM) 46th Annual Critical Care Congress in Honolulu last week suggest that all heart surgery patients are at risk for Retained Blood Syndrome, not just high-risk patients, as previously assumed. All patients having heart surgery are required to have … Continued

Ablexis Continues Expansion of List of Licensees of AlivaMab Mouse BURLINGAME, Calif., Jan. 12, 2017 (GLOBE NEWSWIRE) — Ablexis, LLC announced today that it has entered into a non-exclusive, perpetual license agreement with the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) in New York City to provide access to the AlivaMab Mouse for antibody drug discovery … Continued

BURLINGAME, Calif.–(BUSINESS WIRE)– Ablexis, LLC announced today the expansion of the roster of licensees of its AlivaMab Mouse technology to include an additional top 15 pharmaceutical company. This perpetual, non-exclusive license provides the licensee with its own colony of AlivaMab Mouse and broad rights to use the AlivaMab Mouse for antibody drug discovery and development. … Continued

AlivaMab Mouse Is Next-Generation Antibody Drug Discovery Platform of Choice for Top Pharmas BURLINGAME, Calif.–(BUSINESS WIRE)– Ablexis, LLC announced today the expansion of the roster of licensees of its AlivaMab Mouse technology to include an additional top 15 pharmaceutical company. This perpetual, non-exclusive license provides the licensee with its own colony of AlivaMab Mouse and … Continued

SHELTON, CT–(Marketwired – July 11, 2016) – Spine Wave, Inc. is committed to the commercialization of high-quality, innovative medical devices for the treatment of spinal disorders. Spine Wave’s commitment was demonstrated by its previously announced acquisition of rights in the True Position® Pivoting Spacer System from Atlas Spine on February 23, 2016. Since then, Spine … Continued

IRVINE, Calif., June 21, 2016 /PRNewswire/ — AiVita Biomedical, a therapeutic development company focused on regenerative and curative medicines, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to begin a Phase II clinical study. The study will investigate the efficacy of AiVita’s novel immunotherapy … Continued

IRVINE, Calif., June 10, 2016 /PRNewswire/ — AiVita Biomedical, a therapeutic development company focused on regenerative and curative medicines, today announced it has completed a $2 million Series A round of equity investment. The capital comes from California Technology Ventures (CTV), a Southern California venture capital firm that focuses its investments in the fields of … Continued

Apple has once again chosen to spotlight a third-party product with prime shelf space at its retail stores, partnering with Gamevice to push sales of its lineup of iOS-compatible gaming controllers. Starting Wednesday, June 15 – Gamevice’s attachable gaming pads for iPhone and iPad are now available in all Apple retail stores worldwide. In addition, … Continued